Sign up
Pharma Capital

Imagion Biosystems teams with Dutch partner for breast cancer studies

Imagion’s bio-imaging detection technology uses disease-specific targeting nanoparticles.
cancer cells
Toxicology studies to commence in Q1 2018

Imagion Biosystems (ASX:IBX) has partnered with ChemConnection to produce MagSense™ nanoparticle formulations for its planned HER2 breast cancer human clinical studies.

ChemConnection is a development and manufacturing company based in the Netherlands, with extensive experience in producing nanoparticle-based products and medicines.

Imagion’s MagSense bio-imaging detection technology uses disease specific targeting nanoparticles and detectors to locate tumours and other diseased cells by their molecular signature.

The manufacturing procedures for the MagSense™ HER2 breast cancer test formulation will be as per current good manufacturing practices (cGMP), a regulatory requirement for human testing.

The method transfer of the proprietary nanoparticle formulation will commence immediately.

ChemConnection will initially produce a pilot lot of material which will be used for stability and toxicity studies that are needed before first-in-human testing can begin.

The safety toxicology studies are expected to commence in the first quarter of 2018.

Imagion commenced trading on the ASX in June 2017 after raising $12 million.

The company’s shares are trading circa 7% higher intra-day, at $0.145.



Register here to be notified of future IBX Company articles
View full IBX profile

Imagion Biosystems Ltd Timeline

View All

Related Articles

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.